At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- empasiprubart (biological), IVIg (biological), empasiprubart-placebo (other), IVIg-placebo (other)
- How long the study runs
- Study runs about 61 months (dates as stated)
- About the drug or intervention
- empasiprubart — biological: Intravenous infusion of empasiprubart · IVIg — biological: Intravenous infusion of IVIg · empasiprubart-placebo — other: A placebo resembling the empasiprubart treatment · IVIg-placebo — other: A placebo resembling the IVIg treatment
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 218
- Started
- 2025-08-22
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for chronic inflammatory demyelinating polyneuropathy
- • Phase3 - 218 participants
- • The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with chronic inflammatory demyelinating polyneuropathy
Where?
- • Salford - Salford Royal Hospital - PPDS
- • Leeds - Leeds General Infirmary
- • London - The National Hospital for Neurology and Neurosurgery - PPDS
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- ✓Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner...
- ✓Has responded to IVIg in the past 5 years
- ✓Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose...
- ✓Has residual disability and active disease
Who cannot take part
- ✗Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
- ✗Use of other long-acting immunomodulatory treatment
See the full criteria
Where Is This Study? (3 UK sites)
Salford Royal Hospital - PPDS
Salford M6 8HD, United Kingdom
Leeds General Infirmary
Leeds LS1 3EX, United Kingdom
The National Hospital for Neurology and Neurosurgery - PPDS
London WC1N 3BG, United Kingdom
How to Get in Touch
Sabine Coppieters, MD
Sponsor contactCONTACT